https://pittplusme.org/study/1658
NASH CC90001 Study
This study is not currently recruiting. Please check back at a later time.
STUDY BASICS
Have you been diagnosed with nonalcoholic steatohepatitis (NASH)? If so, you may be able to participate in a study to test the effects of the study drug called CC-90001 on your liver, and to see how well your body tolerates the study drug. Involves multiple visits over 7-8 years that will include up to 3 liver biopsies. Participants will be compensated per completed study visit.
IRB: SSU00080922
- Celgene Corporation - CC-90001-NASH-001, A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS (Pro00033309)
AGE:
18 and up
DURATION:
Up to 28 visits
VISITS:
7-8 years
LOCATION:
UPMC Montefiore Hospital - Oakland
COMPENSATION:
$60 per visit
SHARE STUDY
